Esperion Therapeutics (ESPR) Competitors $1.68 -0.06 (-3.45%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$1.68 +0.01 (+0.30%) As of 03/25/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ESPR vs. CALT, AUPH, GYRE, SPRY, SYRE, SNDX, ADPT, NRIX, ELVN, and NTLAShould you be buying Esperion Therapeutics stock or one of its competitors? The main competitors of Esperion Therapeutics include Calliditas Therapeutics AB (publ) (CALT), Aurinia Pharmaceuticals (AUPH), Gyre Therapeutics (GYRE), ARS Pharmaceuticals (SPRY), Spyre Therapeutics (SYRE), Syndax Pharmaceuticals (SNDX), Adaptive Biotechnologies (ADPT), Nurix Therapeutics (NRIX), Enliven Therapeutics (ELVN), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. Esperion Therapeutics vs. Calliditas Therapeutics AB (publ) Aurinia Pharmaceuticals Gyre Therapeutics ARS Pharmaceuticals Spyre Therapeutics Syndax Pharmaceuticals Adaptive Biotechnologies Nurix Therapeutics Enliven Therapeutics Intellia Therapeutics Esperion Therapeutics (NASDAQ:ESPR) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment. Do analysts prefer ESPR or CALT? Esperion Therapeutics presently has a consensus target price of $6.75, suggesting a potential upside of 301.79%. Calliditas Therapeutics AB (publ) has a consensus target price of $39.25, suggesting a potential downside of 1.88%. Given Esperion Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Esperion Therapeutics is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Esperion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is ESPR or CALT more profitable? Esperion Therapeutics has a net margin of -29.37% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Esperion Therapeutics' return on equity of 0.00% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Esperion Therapeutics-29.37% N/A -10.77% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Do institutionals & insiders hold more shares of ESPR or CALT? 47.4% of Esperion Therapeutics shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 1.0% of Esperion Therapeutics shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community favor ESPR or CALT? Esperion Therapeutics received 600 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 70.21% of users gave Esperion Therapeutics an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformEsperion TherapeuticsOutperform Votes62770.21% Underperform Votes26629.79% Calliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% Which has preferable earnings & valuation, ESPR or CALT? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Esperion Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEsperion Therapeutics$332.31M1.00-$209.25M-$0.25-6.72Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 Does the media refer more to ESPR or CALT? In the previous week, Esperion Therapeutics had 9 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 9 mentions for Esperion Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Esperion Therapeutics' average media sentiment score of 0.61 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Esperion Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Esperion Therapeutics Positive Calliditas Therapeutics AB (publ) Neutral Which has more risk and volatility, ESPR or CALT? Esperion Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. SummaryEsperion Therapeutics beats Calliditas Therapeutics AB (publ) on 14 of the 18 factors compared between the two stocks. Remove Ads Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESPR vs. The Competition Export to ExcelMetricEsperion TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$332.39M$6.99B$5.68B$8.30BDividend YieldN/A2.72%4.55%4.02%P/E Ratio-2.637.2324.5519.25Price / Sales1.00232.30396.2294.31Price / CashN/A65.6738.1634.64Price / Book-0.446.617.064.46Net Income-$209.25M$142.13M$3.19B$247.07M7 Day Performance0.60%1.72%0.18%1.77%1 Month Performance1.82%2.31%5.53%-3.31%1 Year Performance-37.78%-5.07%14.21%5.26% Esperion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESPREsperion Therapeutics3.6259 of 5 stars$1.68-3.4%$6.75+301.8%-35.9%$332.39M$332.31M-2.63200CALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180AUPHAurinia Pharmaceuticals2.6729 of 5 stars$8.40+3.0%$11.50+36.9%+73.7%$1.15B$235.13M-55.96300Positive NewsGYREGyre Therapeutics0.188 of 5 stars$12.32+1.7%N/A-41.3%$1.15B$105.03M0.0040SPRYARS Pharmaceuticals3.3572 of 5 stars$11.64-1.9%$31.00+166.3%+44.0%$1.13B$2.57M-22.8190Earnings ReportAnalyst RevisionSYRESpyre Therapeutics1.8707 of 5 stars$18.71+3.7%$54.83+193.1%-52.8%$1.13B$890,000.00-2.50100SNDXSyndax Pharmaceuticals3.7151 of 5 stars$13.12+1.3%$36.00+174.5%-40.1%$1.13B$23.68M-3.60110Positive NewsADPTAdaptive Biotechnologies3.4601 of 5 stars$7.57+4.0%$9.10+20.1%+169.9%$1.12B$178.96M-6.94790NRIXNurix Therapeutics2.0408 of 5 stars$13.83+1.7%$30.88+123.4%-7.0%$1.05B$54.55M-4.78300ELVNEnliven Therapeutics2.8775 of 5 stars$20.99+1.2%$38.25+82.2%+19.9%$1.02BN/A-11.0350NTLAIntellia Therapeutics4.4718 of 5 stars$9.74+6.5%$37.56+285.7%-67.5%$1.01B$57.88M-1.79600Analyst Revision Remove Ads Related Companies and Tools Related Companies Calliditas Therapeutics AB (publ) Competitors Aurinia Pharmaceuticals Competitors Gyre Therapeutics Competitors ARS Pharmaceuticals Competitors Spyre Therapeutics Competitors Syndax Pharmaceuticals Competitors Adaptive Biotechnologies Competitors Nurix Therapeutics Competitors Enliven Therapeutics Competitors Intellia Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESPR) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
